PEPFAR Overhaul Puts Global Antiretroviral Supply Chain at Risk: 8.7M Patients Impacted

The biotech and pharma sectors have long integrated PEPFAR’s steady purchasing power into their global supply chain strategies. Companies producing generics and innovator antiretrovirals face immediate uncertainty: a sudden halt in orders could fill warehouses, destabilize pricing, and jeopardize partnerships with local distributors in endemic regions. Moreover, the loss of US-funded health infrastructure may slow recruitment for HIV clinical trials and undermine real-world evidence generation that feeds regulatory filings.

The United States’ flagship global HIV/AIDS initiative, the President’s Emergency Plan for AIDS Relief (PEPFAR), is heading toward a financial cliff that threatens to disrupt treatment for more than 8.7 million patients, predominantly in Africa. In September 2026, 120 funding awards administered by the US Centers for Disease Control and Prevention (CDC) are set to expire, with no concrete replacement mechanism in place. This coincides with a major restructuring led by the US State Department, which in May 2026 issued internal guidance to assume greater control over global health programs previously managed jointly by the CDC, the US Agency for International Development (USAID), and other agencies. The overhaul aims to “streamline” PEPFAR but has drawn sharp criticism from public health experts who warn that sidelining the CDC’s scientific expertise could severely erode the initiative’s effectiveness. Analysts at the Health Security Policy Academy have described the potential outcome as “a second global health woodchipper,” referring to the abrupt destruction of operational systems that currently sustain patient care.

“

The biotech and pharma sectors have long integrated PEPFAR’s steady purchasing power into their global supply chain strategies.

Since its establishment by the Bush administration in 2003, PEPFAR has saved an estimated 26 million lives and prevented millions of new HIV infections through the wide-scale delivery of antiretroviral therapy (ART), testing, and prevention services. The program has become a cornerstone of the global HIV response, funding not only direct clinical services but also health workforce training, supply chain logistics, and disease surveillance infrastructure in over 50 countries. The impending expiration of the 120 CDC-led awards, which cover a substantial portion of PEPFAR’s implementation footprint, raises the immediate risk of treatment interruptions. Without a transition plan, the October 1, 2026, start of the new fiscal year could mark a sudden halt to services for millions, leading to treatment gaps that increase viral load, foster drug resistance, and accelerate HIV transmission within communities.

The restructuring itself pivots around the State Department assuming “greater control” over the initiative. While some degree of consolidation could theoretically improve coordination, critics argue that moving management away from public health agencies like the CDC—which has decades of on-the-ground epidemiological expertise—risks politicizing the program and undercutting its technical rigor. The internal guidance obtained by CNN indicates that the new approach will be implemented “swiftly,” a pace that further compounds uncertainty among implementing partners, recipient country governments, and patients. Many of these partners have already begun contingency planning, but lower-income nations lack the fiscal space to absorb sudden funding cuts for such an essential health service.